Biomeme's platform transforms your smartphone into a mobile lab for advanced DNA diagnostics and real-time disease surveillance. The system includes a docking station for real-time PCR, a mobile app to control the system and analyze results, and targeted test kits for preparing samples and identifying pathogens or diseases by their specific DNA or RNA signatures. The cutting edge platform performs to the gold standard used by the world's most advanced central labs but requires no lab equipment or special experience to use.
The low-cost, user-friendly system enables mobile testing at the point-of-need for health care (mobile clinics, disease tracking, home use), agriculture (plant disease tracking, food safety), vector surveillance (Malaria, West Nile mosquitos), veterinary medicine, environmental monitoring (soil and water safety), and even education and citizen science.
|
|
|
|
|
51-200 employees
View all Biomeme, Inc. employees
|
|
|
Biotechnology
|
|
|
$1M–$10M
|
|
|
(215) 239-1930
|
|
|
401 N Broad St, Suite 222, Philadelphia, Pennsylvania 19108, US
|
|
|
2012
|
|
|
Biotech, Mobile Health, Environmental Testing, Infectious Disease Testing, Food Safety Testing, Stem Education Technology, Real-Time Pcr, Biothreat Testing, Diagnostics And Surveillance
|
Max Perelman is the CEO of Biomeme, Inc.. To contact Max Perelman email at [email protected], [email protected] or [email protected]. Or you may call +1 (831) 917-7641
The decision makers in Biomeme, Inc. are Dave Kovscek, Jesse Vanwestrienen, Katie Edwards, etc. Click to Find Biomeme, Inc. decision makers emails.
Biomeme, Inc. headquarters is located at 401 N Broad St, Suite 222, Philadelphia, Pennsylvania 19108, US.
Biomeme, Inc. generates an estimated $1M–$10M annually, based on industry analysis and publicly available market data.
You can contact Biomeme, Inc. by calling (215) 239-1930.
Find accurate personal emails, work emails and phone numbers for employees
Accelerate prospecting with instant access to 350M professionals from 40M companies with the right contact details.